Argenica Therapeutics (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate "significantly" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.
The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.
It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.
The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.
The data verifies data received from previous studies.
The firm's shares rose past 1% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.